YARNO WENDY L 4

What Happened
Wendy Yarno, a director of IDEAYA Biosciences, was granted a derivative equity award on 2026-06-16 covering 20,000 shares. The Form 4 reports the acquisition as an award (transaction code A) with an acquisition price of $0.00 and total reported value of $0. This reflects an option-style award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (timely filing).
• Reported transaction: Award/grant of 20,000 derivative securities at $0.00 (code A).
• Shares owned after transaction: Not specified on the public summary of the filing.
• Footnote: 100% of the shares subject to the option vest in full on the earlier of (i) the first anniversary of the grant or (ii) immediately prior to the next Annual Meeting, subject to continued Board service.
• No 10b5-1, tax-withholding sale, or immediate sale reported.

Context
The filing indicates an equity award (option-style) granted to a board member as compensation; such awards don’t represent an immediate market purchase or sale and often vest over time. Because the exercise price/other economic terms beyond vesting aren’t detailed in the Form 4 summary, this does not by itself indicate liquidity or a trading intent — it’s a standard director compensation event.